Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
Tags :Victoria Marty
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. Through this
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
The Swiss e-commerce agency and software house specializing in the design, development and operation of e-commerce solutions for SMEs, MySign has becomes part of the German Allgeier Group. The IT and software services company Allgeier
Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, successfully closes CHF 100 million (approximately USD 110 million) in Series C financing Round. The financing was co-led by new investors
